Get the Stockscreener App
4.19
6.35%
0.25
After Hours:
4.16
-0.03
-0.72%
Precigen Inc stock is traded at $4.19, with a volume of 3.70M.
It is up +6.35% in the last 24 hours and up +26.20% over the past month.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
See More
Previous Close:
$3.94
Open:
$3.95
24h Volume:
3.70M
Relative Volume:
0.79
Market Cap:
$1.48B
Revenue:
$9.68M
Net Income/Loss:
$-250.64M
P/E Ratio:
-2.9933
EPS:
-1.3998
Net Cash Flow:
$-89.83M
1W Performance:
+28.92%
1M Performance:
+26.20%
6M Performance:
+33.44%
1Y Performance:
+237.90%
1-Day Range:
$3.92
$4.20
1-Week Range:
$3.29
$4.20
52-Week Range:
$1.11
$5.465
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
4.19 | 1.39B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Precigen, Inc. (PGEN) Poised for Growth on Respiratory Papillomatosis Treatment Prospects - Yahoo Finance
Precigen (PGEN) Is Up 7.4% After Surging Revenue And Wider 2025 Losses Are Reported – Has The Bull Case Changed? - simplywall.st
Precigen Stock Hits Day Low of $3.94 Amid Price Pressure - Markets Mojo
PGEN Should I Buy - Intellectia AI
Precigen to Participate in H.C. Wainwright Virtual Fireside Chat - Intellectia AI
Insider Selling: Precigen (NASDAQ:PGEN) Director Sells 4,772,781 Shares of Stock - MarketBeat
PGEN SEC FilingsPrecigen Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
PGEN.O Technical Analysis & Stock Price Forecast - Intellectia AI
PGEN PE Ratio & Valuation, Is PGEN Overvalued - Intellectia AI
Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Hold" from Brokerages - marketbeat.com
Precigen gains after 2025 results on Papzimeos' outlook - MSN
Precigen, Inc. (NASDAQ:PGEN) Q4 2025 earnings call transcript - MSN
PGEN.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
4,772,781 Precigen (PGEN) shares sold by entities tied to Randal Kirk - stocktitan.net
Randal J. Kirk (PGEN) entities sell 4.8M shares, still hold over one-third stake - stocktitan.net
Precigen Details Papzimeos Commercial Launch, Hub Growth and J-Code Catalyst at H.C. Wainwright Chat - MarketBeat
Precigen (NASDAQ:PGEN) Stock Price Up 11.2%What's Next? - marketbeat.com
These analysts boost their forecasts on Precigen following Q4 results - MSN
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31 - StreetInsider
[144] PRECIGEN, INC. SEC Filing - Stock Titan
Precigen (NASDAQ:PGEN) Shares Down 9%Time to Sell? - marketbeat.com
HC Wainwright Estimates Precigen's Q1 Earnings (NASDAQ:PGEN) - marketbeat.com
Precigen (PGEN) Is Up 11.9% After PAPZIMEOS’ Launch Shifts Focus Toward Commercial Revenue Model - simplywall.st
Precigen, Inc. (PGEN) reports Q4 loss, lags revenue estimates - MSN
Precigen (NASDAQ:PGEN) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
Precigen, Inc.FinancialContentStock Market - markets.financialcontent.com
HC Wainwright Has Positive Estimate for Precigen Q3 Earnings - MarketBeat
Discover Precigen And 2 Other Insider-Favored Growth Stocks - Yahoo Finance
Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge? - Yahoo Finance
Precigen Earnings Call Signals Powerful Launch Momentum - tipranks.com
Analyst Upgrade: Whats the beta of Precigen Inc stockMarket Weekly Review & Fast Gain Stock Tips - baoquankhu1.vn
Precigen: The Best Potential Blockbuster You've Never Heard Of (Your ENT Has) - Seeking Alpha
These Analysts Boost Their Forecasts On Precigen Following Q4 Results - Benzinga
Precigen (PGEN) Soars 26% Despite Missed Revenue Estimates - GuruFocus
Precigen (NASDAQ:PGEN) Shares Gap Up Following Analyst Upgrade - MarketBeat
Precigen (PGEN) Shares Surge on Positive Q1 Outlook Despite Earnings Miss - GuruFocus
Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday - Benzinga
Precigen (NASDAQ:PGEN) Price Target Raised to $9.00 at Citizens Jmp - MarketBeat
PGEN: Analyst Jason N. Butler Raises Price Target to $9 | PGEN S - gurufocus.com
H.C. Wainwright raises Precigen stock price target on sales growth - Investing.com UK
Precigen stock gains on Q1 2026 outlook (PGEN:NASDAQ) - Seeking Alpha
PGEN: HC Wainwright & Co. Raises Price Target to $10.00 | PGEN S - GuruFocus
H.C. Wainwright raises Precigen stock price target on sales growth By Investing.com - Investing.com India
Precigen (NASDAQ:PGEN) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Q4 2025 Earnings Call Transcript - Insider Monkey
Precigen (PGEN) Reports Strong Q4 2025 with PAPZIMEOS Launch - gurufocus.com
Citizens raises Precigen stock price target on strong PAPZIMEOS sales - Investing.com UK
Citizens raises Precigen stock price target on strong PAPZIMEOS sales By Investing.com - Investing.com Australia
Precigen Achieves First Commercial Revenue in 2025 with FDA Approval and Strong US Launch of PAPZIMEOS for RRP - Minichart
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):